DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer Sells 33,359 Shares

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

DexCom Stock Up 1.4 %

Shares of DXCM traded up $1.19 during midday trading on Thursday, reaching $87.62. 2,123,429 shares of the stock were exchanged, compared to its average volume of 3,649,357. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $34.22 billion, a price-to-earnings ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12. The firm has a 50 day simple moving average of $80.22 and a 200-day simple moving average of $76.59. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Sanford C. Bernstein lifted their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares during the period. Jennison Associates LLC boosted its stake in DexCom by 10.3% in the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after buying an additional 710,858 shares in the last quarter. Groupama Asset Managment increased its position in shares of DexCom by 1.1% during the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after purchasing an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.